Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma Inc (NASDAQ: CUE) is a clinical-stage biopharmaceutical company pioneering targeted immunotherapies through its innovative Immuno-STAT platform. This page serves as the definitive source for official company announcements, research developments, and strategic updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory milestones, and partnership announcements. Our collection includes updates on CUE-100 series candidates for oncology applications and autoimmune disease programs, along with financial reporting and executive commentary.
All content is sourced directly from company filings and authorized communications, ensuring reliability for those monitoring advancements in T cell-modulating therapies. Key focus areas include phase 1/2 trial results, platform technology enhancements, and collaboration updates with leading research institutions.
Bookmark this page for streamlined access to Cue Biopharma's latest scientific achievements and corporate developments in the competitive immunotherapy landscape. Check regularly for real-time updates on this innovative biologics developer.
On February 1, 2021, Cue Biopharma (Nasdaq: CUE) commenced a Phase 1 dose escalation clinical trial for CUE-101, combined with Merck's KEYTRUDA (pembrolizumab), aimed at treating HPV+ recurrent/metastatic head and neck squamous cell carcinoma. Preliminary results from monotherapy trials indicate CUE-101 is well tolerated and shows early evidence of clinical activity. The trial seeks to explore the synergistic effects of the combination therapy, potentially enhancing anti-tumor responses.
Cue Biopharma (Nasdaq: CUE) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. A pre-recorded fireside chat will be available for participants starting November 23, 2020, at 10:00 a.m. EST, on the Company’s website. Cue Biopharma is focused on engineering a new class of injectable biologics aimed at selectively engaging and modulating T cells to treat cancer, infectious, and autoimmune diseases using its proprietary platform, Immuno-STAT™.
On November 19, 2020, Cue Biopharma (CUE) announced the extension of its research collaboration with Merck, originally established in 2017, aimed at developing therapies for type 1 diabetes and another autoimmune disease. This extension is supported by promising preclinical data and will provide Cue Biopharma with additional financial research support to further explore biologics aimed at identifying clinical candidates. The company emphasizes the potential of its Immuno-STAT™ platform in targeting T cells effectively within the body.
Cue Biopharma, Inc. (Nasdaq: CUE) reported a business update for Q3 2020, highlighting progress in the Phase 1 trial of CUE-101, now entering cohort 7 dosing at 8mg/kg. The company recorded collaboration revenue of $704,000, down from $984,000 in Q3 2019. Operating expenses rose to $10.8 million, driven by increased clinical activities and R&D costs. Net loss was $10.0 million, compared to a loss of $7.0 million in the prior year. As of September 30, 2020, Cue Biopharma held $91.8 million in cash and marketable securities, expected to fund operations into Q2 2022.
Cue Biopharma (Nasdaq: CUE) has announced participation in two upcoming virtual healthcare conferences: the Stifel Virtual Healthcare Conference on November 18, 2020, and the Jefferies Virtual London Healthcare Conference on November 19, 2020. Presentations will cover the company's Immuno-STAT™ platform, ongoing Phase 1 trial of CUE-101 for HPV16-driven head and neck cancer, and highlight future milestones. Webcasts for both events will be available on Cue Biopharma's website.
Cue Biopharma (Nasdaq: CUE) announced a conference call on November 17, 2020, at 4:30 p.m. EST, to update stakeholders on its business progress. The executive team will discuss findings from cohorts 4, 5, and 6 of its ongoing Phase 1 clinical trial of CUE-101, targeting HPV16-driven head and neck cancer. The call will also cover advancements in technology platforms, pipeline updates, and strategic milestones. Access to live and archived versions of the event will be available on the company's website.
Cue Biopharma (CUE) has appointed Tamar Howson to its board of directors, enhancing its business development capabilities. Howson, a veteran in the biopharmaceutical industry with over 30 years of experience, has held significant roles in renowned companies. Her expertise is anticipated to significantly aid Cue Biopharma's corporate development efforts in targeted immunotherapy. This leadership change aims to strengthen the company's strategic execution and foster growth as it advances its proprietary platform, Immuno-STAT™, designed to engage targeted T cells effectively.
On September 15, 2020, Cue Biopharma announced the publication of groundbreaking preclinical data in Nature Methods focusing on their Immuno-STAT platform, which utilizes dimeric protein scaffolds for targeted detection of tumor antigen-specific T cells. This innovative immuno-positron emission tomography (immunoPET) approach enhances the ability to visualize T cells within tumors, potentially transforming treatment methodologies for cancer and other diseases. The feasibility of using these techniques for prognostics and diagnostics was also highlighted, showcasing strong clinical implications.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
